Acute Lymphoblastic Leukemia News and Research

RSS
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.
New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia

New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia

Hollings Cancer Center researcher awarded NCI grant to pursue early investigator studies in leukemia

Hollings Cancer Center researcher awarded NCI grant to pursue early investigator studies in leukemia

“Batman Sam” fights cancer with care from Johns Hopkins Children’s Center

“Batman Sam” fights cancer with care from Johns Hopkins Children’s Center

An existing drug may function as targeted therapy for ALL in children

An existing drug may function as targeted therapy for ALL in children

Study illuminates genetic understanding of aggressive childhood leukemias

Study illuminates genetic understanding of aggressive childhood leukemias

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

International collaboration aims to develop better therapy for childhood acute lymphoblastic leukemia

International collaboration aims to develop better therapy for childhood acute lymphoblastic leukemia

Comprehensive genomic sequencing essential to capitalize precision medicine for pediatric cancer care

Comprehensive genomic sequencing essential to capitalize precision medicine for pediatric cancer care

Chemotherapy drugs can induce mutations that lead to relapse in pediatric ALL patients

Chemotherapy drugs can induce mutations that lead to relapse in pediatric ALL patients

FDA approves alternative component of chemotherapy regimen to treat acute lymphoblastic leukemia

FDA approves alternative component of chemotherapy regimen to treat acute lymphoblastic leukemia

New risk score system to accurately predict leukemia relapse

New risk score system to accurately predict leukemia relapse

Three CU researchers recognized for contributions to immunotherapy in childhood cancer

Three CU researchers recognized for contributions to immunotherapy in childhood cancer

New research uncovers substantial differences in rates of childhood cancers

New research uncovers substantial differences in rates of childhood cancers

LIM domain only 1 gene contributes to the tumorigenesis of multiple cancers

LIM domain only 1 gene contributes to the tumorigenesis of multiple cancers

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Kinase inhibitors could provide an effective way to treat high-risk leukaemia

Kinase inhibitors could provide an effective way to treat high-risk leukaemia

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

Lengthy treatment with low-dose 6-mercaptopurine inhibits resistant triple-negative breast cancer cells

Novel approach to immunotherapy design could pave the way for new brain cancer treatments

Novel approach to immunotherapy design could pave the way for new brain cancer treatments

New combination treatment could benefit T-ALL patients who do not respond to chemotherapy

New combination treatment could benefit T-ALL patients who do not respond to chemotherapy

Immunocompromised children and young adults may experience prolonged SARS-CoV-2 infection

Immunocompromised children and young adults may experience prolonged SARS-CoV-2 infection

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.